Lung Cancer Clinical Trial

A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

Summary

The purpose of this study is to determine the maximum tolerated dose and assess the safety and tolerability of escalating doses of BMS-663513 when given in combination with either radiotherapy alone or radiotherapy plus paclitaxel and carboplatin.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

NSCLC who are eligible to receive a 6 week course of RT
Part 1 - not candidates for definitive RT
Part 2 - candidates for definitive RT

Exclusion Criteria:

Severe COPD, pulmonary infection or interstitial pneumonitis
Recent cellulitis
Autoimmune disease

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

35

Study ID:

NCT00461110

Recruitment Status:

Terminated

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

The Cancer Institute Of New Jersey
New Brunswick New Jersey, 08901, United States
Nyu Clinical Cancer Center
New York New York, 10016, United States
Thomas Jefferson Univ Hospital
Philadelphia Pennsylvania, 19107, United States
University Of Texas Southwestern Medical Center
Dallas Texas, 75390, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

35

Study ID:

NCT00461110

Recruitment Status:

Terminated

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider